Lentiviral Vector (LVV) Platform for CAR Engineering

Online Inquiry

Background Platforms What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a Lentiviral Vector (LVV) Platform for CAR Engineering to address key challenges in cell therapy development, including low CAR transduction efficiency, unstable gene expression, and difficulties scaling viral vector production. This service enables accelerated immune cell engineering through optimized viral packaging systems, improved vector design, and high-yield production workflows. By incorporating advanced envelope engineering, stable producer cell lines, and transduction enhancement strategies, the platform supports efficient gene delivery into T cells and NK cells while improving consistency, safety, and scalability for both research and translational applications.

Introduction

Lentiviral vectors (LVVs) are widely used gene delivery platforms in cell therapy development due to their ability to efficiently introduce large genetic sequences and support stable expression in dividing and non-dividing cells. Recent advances in lentiviral engineering have expanded their applications in CAR-T, CAR-NK, and other immune cell therapies. Research literature highlights LVV as a valuable tool for achieving durable CAR expression while enabling flexible construct optimization for diverse therapeutic strategies.

Fig.1 Bioprocessing of viral vectors and autologous CAR-T cell therapy. (OA Literature) Fig.1 Biomanufacturing for viral vectors and autologous CAR-T therapeutics.¹

Our Platforms

The successful development of CAR-based therapies requires reliable gene delivery systems capable of achieving stable and functional expression of engineered receptors. Creative Biolabs provides integrated LVV solutions to support researchers throughout the CAR engineering process, from initial vector design to functional evaluation. Our LVV platform assists projects by providing:

Customized CAR Lentiviral Vector Design: Support for various CAR architectures, including single-target, multi-target, and next-generation CAR formats.
Optimized Vector Construction: Development of expression cassettes designed for improved stability, expression consistency, and downstream application compatibility.
High-Quality Lentiviral Production: Generation of research-grade and preclinical-use lentiviral materials suitable for immune cell engineering studies.
CAR Cell Generation Support: Assistance with lentiviral-mediated modification of T cells, NK cells, and other immune cell populations.
Comprehensive Characterization: Evaluation of vector quality, transduction performance, and CAR expression profiles.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Test of High-Efficiency Lentiviral & Retroviral Vector (LVV/RVV) Engineering Platforms. (Creative Biolabs Original)

This platform features optimized CAR gene transfer to elevate transduction performance. Clinical-grade packaging cell lines realize stable, scalable viral preparation. Third-gen split-packaging plus SIN design cuts recombination risks, supporting compliant high-quality vectors for translational CAR-T/CAR-NK development.

Our Workflow

Clients need to supply CAR construct details, target immune cell varieties and project indexes, alongside optional specifications on promoters, backbones and viral delivery to kick off relevant projects.

Workflow of High-Efficiency Lentiviral & Retroviral Vector (LVV/RVV) Engineering Platforms. (Creative Biolabs Original)

Clients obtain validated CAR-positive immune cells, complete viral production QC documents and functional assay reports, plus optional scalable process optimization advice for follow-up research.

Benefits

Lentiviral vector engineering services, from CAR construct optimization to functional validation of engineered immune cells.
Customized LVV platform development tailored to specific CAR designs, target antigens, immune cell types, and project objectives.
High-titer viral vector production workflows with optimized packaging systems for reliable gene delivery into T cells, NK cells, and other immune cell populations.
Flexible support for diverse CAR formats, including single-target, multi-target, and next-generation CAR constructs.
Analytical characterization, including vector quality assessment, transduction efficiency evaluation, CAR expression profiling, and functional activity testing.

FAQs

Q1: What is the main advantage of using LVV over RVV systems?

A1: LVV systems can efficiently transduce both dividing and non-dividing immune cells, making them suitable for a broader range of cell therapy applications. They are commonly used when stable gene expression is required in primary T cells, NK cells, and other immune cell populations.

Q2: How is transduction efficiency improved in this platform?

A2: Transduction efficiency is enhanced through multiple optimization strategies, including vector backbone refinement, envelope engineering, viral production optimization, and controlled immune cell activation protocols. These approaches help improve gene delivery efficiency, increase CAR expression levels, and maintain cell viability and functionality throughout the engineering process.

Q3: Can the platform support different CAR designs and project requirements?

A3: Yes. Creative Biolabs offers highly flexible and customizable LVV solutions that support a wide variety of CAR architectures, including different antigen-binding domains, signaling modules, and costimulatory domains. The platform can be adapted to specific target antigens, immune cell types, and research objectives to meet diverse project needs.

Partner with Us

Creative Biolabs' Lentiviral Vector (LVV) Platform for CAR Engineering provides a modular and scalable solution for immune cell engineering, enabling efficient gene delivery, stable CAR expression, and reproducible manufacturing workflows. The platform is designed to support diverse CAR development needs from early-stage research to preclinical validation, with flexible customization options for different therapeutic targets.

How to Contact Us

For detailed project discussions, technical inquiries, pricing information, or customized service proposals, don't hesitate to contact our team. We welcome projects ranging from early-stage research and proof-of-concept studies to advanced preclinical development programs.

Reference

Labbé, Roman P et al. "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives." Viruses vol. 13,8 1528. 2 Aug. 2021. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/v13081528

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.